Zenobia Therapeutics was founded in 2008 by Drs Vicki Nienaber and Robert Meadows. Zenobia’s founders are pioneers in the field of fragment-based lead discovery (FBLD) contributing to the model NMR screening paradigm, SARbyNMR (1,2) and inventing the first crystallographic screening method, CrystaLead (3). Recognizing that diseases of the CNS are a significant unmet medical need, Zenobia Therapeutics quickly adapted the strengths of FBLD to address one of the biggest challeng

Welcome to our new blog. Here, we will be sharing thoughts and opinions based upon our 20-30 years of experience in fragment screening and structural biology. We will share data we have generated and significant findings that we feel apply to the structural biology and fragment screening field. We welcome your comments on the utility of our products, challenges you face in your research and your opionions on the field in general. Zenobia Fragments became an official entity i